Targets › ITGB2
1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology.
Integrin ITGAL:ITGB2 is a receptor for ICAM1, ICAM2 and ICAM3. Integrin ITGAL:ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Integrins ITGAM:ITGB2 and ITGAX:ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. (UniProt, P05107)
Open in Phaseline: the race on ITGB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lunan Better Pharmaceutical | Lifitegrast Integrin alpha-L/beta-2 (LFA-1) antagonist | ITGAL, ITGB2 | Phase 3 | Dry Eye Disease (DED) | – |
Dry Eye Disease (DED) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.